<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36795366</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN><JournalIssue CitedMedium="Internet"><Volume>2612</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Methods in molecular biology (Clifton, N.J.)</Title><ISOAbbreviation>Methods Mol Biol</ISOAbbreviation></Journal><ArticleTitle>A Unique Multiplex ELISA to Profile Growth Factors and Cytokines in Cerebrospinal Fluid.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>168</EndPage><MedlinePgn>157-168</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-2903-1_12</ELocationID><Abstract><AbstractText>Multiplex arrays designed for enzyme-linked immunosorbent assays (ELISAs) are robust and cost-effective for profiling biomarkers. Identification of relevant biomarkers in biological matrices or fluids helps in the understanding of disease pathogenesis. Here, we describe a sandwich ELISA-based multiplex assay to assess growth factor and cytokine levels in cerebrospinal fluid (CSF) samples derived from multiple sclerosis patients, amyotrophic lateral sclerosis patients, and control subjects without any neurological disorder. Results indicate that multiplex assay designed for the sandwich ELISA method is a unique, robust, and cost-effective method for profiling growth factors and cytokines present in CSF samples.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madiraju</LastName><ForeName>Charitha</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Marshall B. Ketchum University, Fullerton, CA, USA. cmadiraju@ketchum.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sastry</LastName><ForeName>Amani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Noorda College of Osteopathic Medicine, Provo, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oppong</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Marshall B. Ketchum University, Fullerton, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karp</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Marshall B. Ketchum University, Fullerton, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajewska</LastName><ForeName>Maryla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cellestan Immunoquant (CIQ), Inc, Oceanside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajewski</LastName><ForeName>Stan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cellestan Immunoquant (CIQ), Inc, Oceanside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomik</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczudlik</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>QuantiScientifics, LLC, Orange, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Methods Mol Biol</MedlineTA><NlmUniqueID>9214969</NlmUniqueID><ISSNLinking>1064-3745</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid samples (CSFs)</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Growth factors</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis (MS)</Keyword><Keyword MajorTopicYN="N">Multiplex array</Keyword><Keyword MajorTopicYN="N">Sandwich ELISA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36795366</ArticleId><ArticleId IdType="doi">10.1007/978-1-0716-2903-1_12</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Noseworthy JH, Lucchinetti C, Rodriguez M et al (2000) Multiple sclerosis. N Engl J Med 343(13):938&#x2013;952</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200009283431307</ArticleId><ArticleId IdType="pubmed">11006371</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378(2):169&#x2013;180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1401483</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId><ArticleId IdType="pmc">6942519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683&#x2013;747</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.23.021704.115707</ArticleId><ArticleId IdType="pubmed">15771584</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;bel K, Ruck T, Meuth SG (2018) Cytokine signaling in multiple sclerosis: lost in translation. Mult Scler 24(4):432&#x2013;439</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458518763094</ArticleId><ArticleId IdType="pubmed">29512406</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Dreyfus CF (2016) The role of growth factors as a therapeutic approach to demyelinating disease. Exp Neurol 283(Pt B):531&#x2013;540</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2016.02.023</ArticleId><ArticleId IdType="pubmed">27016070</ArticleId><ArticleId IdType="pmc">5010931</ArticleId></ArticleIdList></Reference><Reference><Citation>Imitola J, Chitnis T, Khoury SJ (2005) Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 106(2):163&#x2013;177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2004.11.007</ArticleId><ArticleId IdType="pubmed">15866318</ArticleId></ArticleIdList></Reference><Reference><Citation>Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8(9):a028928</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028928</ArticleId><ArticleId IdType="pubmed">29358317</ArticleId><ArticleId IdType="pmc">6120692</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimone D, Gregory S, Arnason BG et al (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32(1):67&#x2013;74</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(91)90073-G</ArticleId><ArticleId IdType="pubmed">2002092</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita T, Tateishi T, Isobe N et al (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 8(4):e61835</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061835</ArticleId><ArticleId IdType="pubmed">23637915</ArticleId><ArticleId IdType="pmc">3630114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R et al (2019) Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve 59(1):10&#x2013;22</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao MC, Cawston EE, Chen G et al (2022) Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis. BMC Neurol 22(1):216</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02730-1</ArticleId><ArticleId IdType="pubmed">35690735</ArticleId><ArticleId IdType="pmc">9188104</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J et al (2020) Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 7(7):1103&#x2013;1116</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId><ArticleId IdType="pmc">7359115</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats KA, Borchelt DR, Tansey MG et al (2022) Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol Neurodegener 17(1):11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId><ArticleId IdType="pmc">8785449</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster HD (1997) Growth factors and myelin regeneration in multiple sclerosis. Mult Scler 3(2):113&#x2013;120</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859700300210</ArticleId><ArticleId IdType="pubmed">9291164</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino G, Furlan R, Brambilla E et al (2000) Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. J Neuroimmunol 109(1):3&#x2013;9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(00)00295-2</ArticleId><ArticleId IdType="pubmed">10969174</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V et al (2005) Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 65(12):1958&#x2013;1960</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkovi&#x107; F, Castellano B (2016) The role of interleukin-6 in central nervous system demyelination. Neural Regen Res 11(12):1922&#x2013;1923</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.195273</ArticleId><ArticleId IdType="pubmed">28197184</ArticleId><ArticleId IdType="pmc">5270426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharief MK (1998) Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Mult Scler 4(3):169&#x2013;173</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859800400315</ArticleId><ArticleId IdType="pubmed">9762668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner CA, Roqu&#xe9; PJ, Goverman JM (2020) Pathogenic T cell cytokines in multiple sclerosis. J Exp Med 217(1):e20190460</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190460</ArticleId><ArticleId IdType="pubmed">31611252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wullschleger A, Kapina V, Molnarfi N et al (2013) Cerebrospinal fluid Interleukin-6 in central nervous system inflammatory diseases. PLoS One 8(8):e72399</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0072399</ArticleId><ArticleId IdType="pubmed">24015240</ArticleId><ArticleId IdType="pmc">3754988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak D, Szulc-Kuberska J, Stepie&#x144; H et al (1986) Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis. J Neurol 233(6):376&#x2013;377</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313927</ArticleId><ArticleId IdType="pubmed">3492593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, Iwasaki T, Nakamura S et al (1999) FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons. Int J Dev Neurosci 17(3):191&#x2013;200</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0736-5748(99)00026-X</ArticleId><ArticleId IdType="pubmed">10452363</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalabrino G (2022) Newly identified deficiencies in the multiple sclerosis central nervous system and their impact on the remyelination failure. Biomedicine 10(4):815</Citation></Reference><Reference><Citation>Scalabrino G (2022) Epidermal growth factor in the CNS: a beguiling journey from integrated cell biology to multiple sclerosis. An extensive translational overview. Cell Mol Neurobiol 42(4):891&#x2013;916</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00989-x</ArticleId><ArticleId IdType="pubmed">33151415</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul A, Comabella M, Gandhi R (2019) Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med 9(3):a029058</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029058</ArticleId><ArticleId IdType="pubmed">29500303</ArticleId><ArticleId IdType="pmc">6396336</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson RS (2021) Well-based antibody arrays. Methods Mol Biol 2237:11&#x2013;38</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1064-0_2</ArticleId><ArticleId IdType="pubmed">33237405</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson RS (2015) Multiplex ELISA using oligonucleotide tethered antibodies. Methods Mol Biol 1318:181&#x2013;195</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2742-5_18</ArticleId><ArticleId IdType="pubmed">26160576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>